---
title: "management of metastatic disease-of-bladder cancer"
slug: "management-of-metastatic-disease-of-bladder-cancer"
date: "2023-11-22"
enableToc: false
tags:
  - building
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[bladder cancer]]

# management of metastatic disease-of-bladder cancer

- Cisplatin-based chemo is the preferred initial tx (ddMVAC, GC),
  - if eligible 1st line: GC preferred over MVAC d/t equal efficacy w/ less toxicity (less neutropenia,
  - neutropenic sepsis,
  - mucositis) (JCO 2000:18:3068). ddMVAC (q2wk w/ GCSF support) has â†‘ RR,
  - â†“ toxicity compared to MVAC (JCO 2001;19:2638)
- If [[cisplatin ineligible of bladder cancer]]
  - (CrCl â‰¤60 mL/min; ECOG PS â‰¥2; Grade 2 hearing loss/neuropathy; NYHA HF class â‰¥3)
  - but platinum eligible: Use gemcitabine + carboplatin (JCO 2012;30:191) OR if PD-L1 positive: Pembrolizumab (Lancet Onc 2017;18:1483) or atezolizumab (Lancet 2017;389:67)
- If platinum ineligible
  - (CrCl <30 mL/min; ECOG PS >3; neuropathy grade >3; NYHA HF Class >3; ECOG PS 2 & CrCl <30 mL/min): Pembrolizumab or atezolizumab
- Maintenance avelumab â†‘ OS after partial response or stable dz to platinum (NEJM 2020;383:1218)
- [[2nd line of metastatic disease-of-bladder cancer]]
- 3rd line:
  - [[Enfortumab vedotin]] a/w â†‘ OS vs. chemo post platinum & PD-1/L1 inhibitor (NEJM 2021;384:1125); Sacituzumab govitecan a/w RR 27% (JCO 2021;39(22):2474)
- Can consider
  - gemcitabine, docetaxel, paclitaxel monotherapy in later tx lines
